This correlation was particularly pronounced in the adenocarcinoma subtype (p < 0.0001), where the survival of patients with a higher ADAMTS9 gene expression (127 months) was almost twice as long as that of individuals with lower expression (76 months). The gene discussed is ADAMTS9; the disease is adenocarcinoma.